ATRX and central nervous system cancer: As a consequence, a HR of 2.736 indicated that the risk score could significantly contribute to the prediction of survival of glioma patients, eliminating the influence of other factors such as sex, age, grade, radiotherapy, chemotherapy and the molecular status (IDHDampR, TP53.1, EGFR, ATRX and EZH2) (Table 3).